——|——–|———————|
| Mechanism |
Central (brain) |
Peripheral (blood vessels) |
| Target |
MC3/MC4 receptors |
PDE5 enzyme |
| Effect |
Desire + arousal |
Arousal only |
| Works for women |
Yes (studied) |
No |
| Onset |
30-60 minutes |
30-60 minutes |
| Duration |
6-12 hours |
4-6 hours |
PT-141 Research Applications
Female Sexual Dysfunction Research
The most extensively studied application:
Hypoactive Sexual Desire Disorder (HSDD): FDA-approved for premenopausal women
Female Sexual Arousal Disorder (FSAD): Studies in arousal response
Sexual desire: Increased self-reported sexual desire and satisfaction
Distress reduction: Decreased distress related to low sexual desire
Menopause: Research in postmenopausal women with sexual dysfunction
Male Sexual Dysfunction Research
Erectile dysfunction (ED): Studies in men with ED, including PDE5 non-responders
Low libido: Research in hypoactive sexual desire in men
Combination therapy: Studies combining PT-141 with PDE5 inhibitors
Post-prostatectomy: Research in sexual function recovery after surgery
Diabetes-related ED: Studies in men with diabetic erectile dysfunction
Neurological and Psychiatric Research
Emerging research areas:
Depression: MC4 receptor pathways in mood regulation
Anxiety: Potential anxiolytic effects in preclinical models
Reward pathways: Dopamine and reward processing research
Cognitive function: Preliminary studies in cognitive enhancement
Substance abuse: Research in addiction and reward pathways
Metabolic Research
Appetite regulation: MC4 receptor effects on food intake
Energy expenditure: Increased metabolic rate in preclinical models
Body composition: Studies in obesity and weight management
Insulin sensitivity: Potential metabolic benefits
PT-141 Dosage for Research
Important: Dosage information is for research reference only. Research-grade PT-141 is not approved for human use outside of clinical trials.
Female Research Dosage
| Protocol |
Dosage |
Frequency |
Notes |
| FDA-approved (Vyleesi) |
1.75 mg |
As needed, max 1x/24h, 8x/month |
Auto-injector |
| Research peptide (standard) |
0.5-1.0 mg |
As needed, 1-2x/week |
Subcutaneous injection |
| Research peptide (low start) |
0.25-0.5 mg |
As needed |
Titrate based on response |
| Research peptide (higher) |
1.0-1.75 mg |
As needed, max 1x/24h |
Monitor side effects |
Male Research Dosage
| Protocol |
Dosage |
Frequency |
Notes |
| Standard research |
0.5-1.0 mg |
As needed, 1-2x/week |
Subcutaneous injection |
| Low starting dose |
0.25-0.5 mg |
As needed |
Assess tolerance |
| Higher dose studies |
1.0-2.0 mg |
As needed, max 1x/24h |
Monitor blood pressure |
| Combination with PDE5i |
0.5-1.0 mg |
As needed |
With sildenafil/tadalafil |
Research Administration Guidelines
Route: Subcutaneous injection (abdomen, thigh, or upper arm)
Onset: 30-60 minutes after injection
Peak effect: 1-2 hours post-administration
Duration: 6-12 hours (individual variation)
Timing: Administer 45-60 minutes before anticipated sexual activity
Maximum: No more than one dose in 24 hours, no more than 8 doses per month
Reconstitution Guide
Sanitize vial stopper with alcohol swab
Add bacteriostatic water:
– 10mg vial + 2mL BAC water = 5mg/mL (1mg = 0.2mL)
– 10mg vial + 5mL BAC water = 2mg/mL (1mg = 0.5mL)
Swirl gently until fully dissolved
Store in refrigerator at 2-8°C
Use within 30 days of reconstitution
Use our Peptide Calculator for precise dosing volume calculations.
PT-141 Side Effects in Research
Clinical trials and preclinical research have documented the following:
Common Side Effects (>10% in clinical trials)
Nausea: Most common (approximately 40% in clinical trials), usually transient
Flushing: Facial redness and warmth (~20%)
Headache: Mild to moderate (~20%)
Injection site reactions: Redness, pain, or bruising (~15%)
Dizziness: Especially after standing up quickly (~10%)
Less Common Side Effects (1-10%)
Vomiting: At higher doses or in sensitive individuals
Fatigue: Temporary tiredness after administration
Hot flashes: Transient warmth and sweating
Nasal congestion: Stuffy nose (uncommon with injectable form)
Increased blood pressure: Transient BP elevation (monitor in research)
Decreased appetite: Mild food intake reduction
Rare but Important Side Effects (<1%)
Severe nausea/vomiting: Requiring antiemetic treatment
Syncope: Fainting, particularly with rapid onset
Hypertensive crisis: Significant blood pressure elevation (rare)
Allergic reactions: Rash, itching, or anaphylaxis (extremely rare)
Prolonged erection: Priapism (theoretical, not commonly reported)
Contraindications and Research Cautions
Cardiovascular disease: Monitor blood pressure closely
Hypertension: Use with caution, monitor BP
Liver/kidney impairment: Dose adjustment may be needed
Pregnancy/lactation: Not studied, avoid in research
Melanoma history: Theoretical concern with melanocortin activation
Drug interactions: Avoid with other melanocortin agonists
Side Effect Management in Research
Start with lower doses and titrate based on response
Administer with food to reduce nausea
Stay well-hydrated
Use antiemetics if nausea is significant
Monitor blood pressure in at-risk research subjects
Reduce dose or discontinue if side effects are severe
PT-141 vs. Melanotan 2: Comparison
PT-141 was developed from Melanotan 2, but they have important differences:
| Feature |
PT-141 (Bremelanotide) |
Melanotan 2 |
| Primary purpose |
Sexual function |
Tanning |
| Receptor profile |
MC3/MC4 focused |
MC1, MC3, MC4, MC5 |
| Tanning effect |
Minimal |
Strong |
| Nausea |
Moderate |
Moderate-High |
| Appetite suppression |
Mild |
Moderate-Strong |
| Sexual effects |
Strong |
Moderate |
| Half-life |
~1-2 hours |
~1-2 hours |
| FDA approval |
Yes (female HSDD) |
No |
| Research cost |
Higher |
Lower |
Purity and Quality Standards
Research-grade PT-141 should meet these criteria:
HPLC purity: ≥98% (target >99%)
Mass spectrometry: Confirms molecular weight of 1025.2 g/mol
Endotoxin levels: <0.1 EU/μg for in vivo research
Appearance: White to off-white lyophilized powder
Solubility: Readily soluble in bacteriostatic water
Storage: -20°C for long-term, protected from light
CoA: Certificate of Analysis should be available
Important: PT-141 is sometimes confused with other melanocortin peptides. Always verify the correct sequence and molecular weight when sourcing for research.
Hanpro Peptides provides third-party tested PT-141 with full CoA documentation, ensuring research-grade quality and consistency.
Where to Buy PT-141 for Research
Hanpro Peptides offers high-purity PT-141:
Purity: >99% HPLC verified
Available sizes: 10mg vials
Format: Lyophilized powder
Worldwide shipping: 7-15 day delivery with tracking
Quality: Third-party tested with CoA available
Support: Research guidance and reconstitution assistance
Purchase PT-141 Online from Hanpro Peptides — trusted by research facilities worldwide.
Related Research Peptides
Explore these complementary peptides:
Melanotan 2 (MT-2) — Parent compound, tanning + sexual effects
MT-1 (Melanotan 1) — MC1-selective tanning peptide
Semaglutide — GLP-1 weight management research peptide
Tirzepatide — Dual GIP/GLP-1 agonist research peptide
Frequently Asked Questions
How is PT-141 different from Viagra?
PT-141 works centrally in the brain to increase sexual desire and arousal, while Viagra (sildenafil) works peripherally by increasing blood flow to the genitals. PT-141 addresses both desire and arousal, while Viagra only addresses physical arousal. PT-141 has also shown effectiveness in women, while Viagra does not.
How long does PT-141 take to work?
PT-141 typically begins to take effect 30-60 minutes after subcutaneous injection, with peak effects at 1-2 hours. The duration of action is approximately 6-12 hours, though individual response varies.
Is PT-141 FDA approved?
Yes, an auto-injector formulation of Bremelanotide (brand name Vyleesi) was FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. However, the research-grade peptide powder form is not FDA-approved and is intended for laboratory research purposes only.
Can PT-141 be used with Viagra or Cialis?
Some research has investigated combination therapy of PT-141 with PDE5 inhibitors (sildenafil, tadalafil) for erectile dysfunction, particularly in men who do not respond to PDE5 inhibitors alone. However, this combination should only be used in controlled research settings with medical supervision due to potential cardiovascular effects.
What are the most common side effects of PT-141?
The most common side effects in clinical trials were nausea (approximately 40%), flushing (~20%), headache (~20%), injection site reactions (~15%), and dizziness (~10%). Most side effects are transient and resolve within a few hours. Starting with a lower dose can help minimize side effects.
*Disclaimer: This article is for educational and research informational purposes only. PT-141 (Bremelanotide) research-grade peptide is a research-use-only compound. While an FDA-approved formulation exists for specific medical use, the research-grade form discussed here is not approved for human consumption. All information is based on preclinical and clinical research and does not constitute medical advice.*
